CT102 (Baize)

CT102 is an experimental bispecific cell therapy currently in preclinical development by Baize (Shanghai Baize Medical Technology) for the treatment of solid tumors. The therapy is built upon Baize's proprietary nanobody-based cell navigation and control platform, which aims to improve the precision and efficacy of cell-based immunotherapies in the challenging microenvironment of solid malignancies. By utilizing a bispecific approach, CT102 is designed to target two distinct antigens simultaneously, potentially reducing the risk of tumor escape due to antigen heterogeneity. Although the specific molecular targets of CT102 have not been publicly disclosed, the asset represents a key component of Baize's next-generation cell therapy pipeline.